Topical treatments such as imiquimod and 5-fluorouracil are recognised clinical options for managing specific types of basal cell carcinoma in the United Kingdom. These medications are primarily reserved for the superficial subtype of the disease, where the cancerous cells are located in the uppermost layers of the skin. Unlike surgical procedures that physically remove the tumour, these creams work by either stimulating the body’s own immune response or by directly interfering with the ability of cancer cells to multiply. While surgery remains the gold standard for achieving the highest cure rates, topical therapies offer a non-invasive alternative for individuals with low-risk lesions in certain anatomical locations.
What We’ll Discuss in This Article
- How imiquimod stimulates the immune system to target cancer
- The mechanism of 5-fluorouracil in destroying abnormal skin cells
- Success rates of topical creams compared to surgical excision
- Typical treatment schedules and duration for superficial BCC
- Managing the expected skin reactions during the application period
- Clinical criteria for selecting patients suitable for topical therapy
The effectiveness of imiquimod for superficial lesions
Imiquimod, often prescribed under the brand name Aldara, is an immune response modifier that has been licensed for the treatment of small superficial basal cell carcinomas in adults. It works by activating specific receptors in the skin that trigger the production of natural proteins such as interferon, which then direct the immune system to identify and destroy the cancerous cells. The National Health Service explains that imiquimod cream is an effective treatment for small superficial basal cell carcinomas and is often used when surgery is not desirable or practical.
Clinical studies such as the SINS trial in the UK have evaluated the long-term effectiveness of imiquimod. These studies found that approximately eighty-two to eighty-four per cent of superficial lesions treated with imiquimod remained clear after five years. While this is slightly lower than the ninety-seven to ninety-eight per cent success rate achieved with surgery, it represents a high level of efficacy for a non-invasive treatment. The cream is typically applied five times a week for a period of six weeks, and the clinical response is usually assessed several weeks after the course is finished.
How 5-fluorouracil works against skin cancer
5-fluorouracil, commonly known as 5-FU or by the brand name Efudix, is a type of topical chemotherapy that has been used in UK dermatology for several decades. It works as an antimetabolite, which means it mimics the building blocks of DNA and RNA. When the rapidly dividing cancer cells incorporate the medication, it prevents them from reproducing and leads to their destruction while having a much smaller effect on healthy, slow-dividing skin cells. This selective action makes it useful for treating superficial malignancies and pre-cancerous patches.
NICE clinical guidelines state that topical 5-fluorouracil is a recognised management option for superficial basal cell carcinoma, particularly when multiple lesions are present on the trunk or limbs. The typical treatment schedule involves applying the cream once or twice daily for a period of roughly six weeks. Research indicates that the cure rates for 5-fluorouracil are generally in the region of eighty per cent for superficial lesions. Because it directly targets the DNA of the cells, it is highly effective at clearing the visible tumour and any nearby microscopic abnormal cells within the treatment field.
Comparing topical creams with surgical outcomes
When deciding between a cream and surgery, the medical team considers the trade-off between the ease of treatment and the statistical likelihood of a permanent cure. Surgical excision offers a higher overall success rate because the surgeon can verify that the margins are clear of cancer under a microscope. Topical creams, however, avoid the need for local anaesthetic injections, stitches, and the resulting surgical scar. This makes them a popular choice for superficial lesions on the back, chest, or limbs where a minor recurrence might be easily managed if it occurs.
It is important to note that these creams are not suitable for the nodular or infiltrative subtypes of basal cell carcinoma. These variants grow too deeply for the medication to penetrate effectively, meaning the surface might appear to heal while the cancer continues to grow underneath. For this reason, a biopsy is almost always performed before starting a cream to confirm that the tumour is truly superficial. By selecting the correct patient and tumour type, clinicians ensure that the non-surgical approach is both safe and effective.
Expected skin reactions during treatment
A unique aspect of using imiquimod or 5-fluorouracil is the inflammatory reaction that occurs at the treatment site. This reaction is not a side effect in the traditional sense but is evidence that the medication is actively destroying the cancer cells. During the second or third week of treatment, the skin typically becomes red, sore, and scaly. It may also develop shallow erosions or crusting as the abnormal tissue is broken down by the medication or the immune system.
Patients are often advised that if the skin does not show some level of redness or irritation, the treatment may not be working effectively. The intensity of the reaction can vary between individuals and can sometimes be uncomfortable. If the response becomes too severe, a doctor may recommend a short break in treatment or the use of a mild steroid cream to soothe the inflammation. Once the six-week course is complete, the skin usually heals very well over the following month, often leaving a smooth and cosmetically pleasing result with minimal long-term scarring.
Clinical criteria for topical therapy selection
Not every superficial basal cell carcinoma is a candidate for topical treatment. The British Association of Dermatologists and other UK clinical bodies have established criteria to ensure patient safety. Creams are generally reserved for lesions that are less than two centimetres in diameter and are located in low-risk areas. They are often avoided near the eyes, as the cream can cause significant irritation if it comes into contact with the delicate tissues of the eyelid or the conjunctiva.
The patient’s ability to follow a complex application schedule is also considered. Because the treatment lasts for several weeks and requires regular monitoring of the skin reaction, it may not be suitable for individuals who have difficulty reaching the site or who may struggle to remember the daily applications. For those who meet the criteria, topical therapy remains a valuable and highly effective tool in the modern management of non-melanoma skin cancer, providing a successful outcome without the need for a hospital operating theatre.
Conclusion
Creams like imiquimod and 5-fluorouracil are effective treatments for superficial basal cell carcinoma, with success rates of approximately eighty per cent. They offer a non-invasive alternative to surgery for low-risk lesions on the body and limbs. While they cause a significant temporary skin reaction, they typically result in excellent cosmetic outcomes once the healing process is complete.
If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Will the cream leave a scar on my skin?
Most patients find that the skin heals very well with minimal scarring, although there may be some temporary or permanent change in the colour of the skin.
Can I use these creams for a BCC on my nose?
Topical creams are usually avoided on the nose or near the eyes because the skin is thin and the risk of irritation or incomplete treatment is higher.
What happens if I forget to apply the cream for a day?
You should simply continue with your normal schedule the following day; do not apply a double dose to make up for a missed one.
How do I know if the treatment has worked?
Your doctor will perform a follow up check roughly twelve weeks after the treatment ends to ensure the skin has healed and the lesion has disappeared.
Are these creams a type of chemotherapy?
5-fluorouracil is a topical chemotherapy, while imiquimod is an immunotherapy that uses your own body to fight the cancer cells.
Can I go in the sun while using the cream?
You should keep the treated area protected from the sun as the medication can make your skin much more sensitive to ultraviolet radiation.
What if the cancer comes back after using a cream?
If a lesion returns after topical treatment, your specialist will likely recommend surgical excision to ensure the cancer is completely removed.
Authority Snapshot (E-E-A-T)
This article is designed to provide clear and factual information regarding skin health for the general public. The content is written by the Medical Content Team and has been reviewed by Dr. Stefan Petrov. He is a UK-trained physician with an MBBS and postgraduate certifications including Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and the UK Medical Licensing Assessment (PLAB 1 & 2). He has hands-on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient-focused health content and teaching clinical skills to junior doctors.
